Forty-six healthy women received Cyclofem (25mg medroxyprogesterone acetate with sing estradiol cypionate) and other /orly--five women, as control,received oral contraceptive pill (Ortho--Novum 1/35, containing noreth...Forty-six healthy women received Cyclofem (25mg medroxyprogesterone acetate with sing estradiol cypionate) and other /orly--five women, as control,received oral contraceptive pill (Ortho--Novum 1/35, containing norethisterone enantate ling and estradiol valerate 35fig) for nine months. Blood samples were taken during the follicular and luteal phases o/preu treatment, and for Cyclofem group, immediately prior to the 3rd and gth injections and 1 and 3 weeks a/ter the 3rd and gth injections, for Ortho Novum group, blood samples were taken on the irst day o[.the 3rd and gth pill cycles and 1 and 3 weeks later in both cycles. For both groups after at least 3 months nonhormonal method of contraception, blood sampling was repeated at follicular and luteal phases of a normal mentrual cycle.Coagulation and librinolysis parameter were detected including hemoglobin,platelet count, prothrombin time, APTT, fibrinogen, factor Vll, [actor X,plasminogen, in PAl, AT Ill (functional and immunological assays) and protein C.In the Cyclolem group, hemoglobin, platelet count, fibrinogen and /Octor X were not changed. Factor Vll significantly reduced. Prothrombin time and APTT showed minor changes. Plasminogen and protein C decreased while t-- PAl and AT 11.1 increased. These changes showed a dynamic balance between coagulatioll and fibrinolysis. In Ortho---Novum 1/35 group, platelet count, jactor X and [ibrinogen increased and prothrombin time and APTT accelerated. In fibrinolysis and anticoagulation system, plasminogen increased as well as protein C, but AT Ill declined. Those changes showed a tendency o[ hyper-coagulabllity state, fibrinolysis and anticoagulation were enhanced to a certain extent.The result of our study is that there are slight 'changes on coagulation and [ibrinolyls is in Cyclofem injectable contraceptive users.展开更多
The effects of consecutively using the contraceptive injections (Mesigyna or Cyclofem) on both blood coagulation and fibrinolysis were evaluated on 94 Chinese women who had been injected with one of these two injectio...The effects of consecutively using the contraceptive injections (Mesigyna or Cyclofem) on both blood coagulation and fibrinolysis were evaluated on 94 Chinese women who had been injected with one of these two injections once a month for 9 months. To provide the evidences on the safety of long term use, relevant parameters were observed before the treatment, after the injection 3 and 9, as well as 3 months after drug withdrawing. The results were as follows: Among those who had been injected with Mesigyna, the levels of factor VII and factor X declined significantly during treatment. The activity of AT Ⅲ, plasminogen and the concentration of protein C also decreased. Moreover, the corresponding parameters did not recovered to the normal level after stopping treatment. Prothrombin time (PT) and activated partial thromboplastin time (APTT) were prolonged in the early period of treatment, but recovered to the normal at week 47 (injection withdrawn). No or slight change was observed in other parameters. Among the woman injected with Cyclofem, the concentrations of factor VII and plasminogen decreased over time, while the tissue plasminogen activator inhibitor (t PAI) levels increased after the 9 th injection and recovered to normal at week 47 after discontinuation of treatment. The results suggested that some significant parameter changes of coagulation and of fibrinolysis could be detected among long term users, but their impact on the fibrinolysis system was not obvious. The observed phenomenon did not show a tendency to facilitate thromboembolism and possibility of being harmful to the users. Thus, the observed changes should be regarded as the reactions to keep the equilibrium between coagulation and fibrinolysis and had no marked clinical pathological significance on the users.展开更多
文摘Forty-six healthy women received Cyclofem (25mg medroxyprogesterone acetate with sing estradiol cypionate) and other /orly--five women, as control,received oral contraceptive pill (Ortho--Novum 1/35, containing norethisterone enantate ling and estradiol valerate 35fig) for nine months. Blood samples were taken during the follicular and luteal phases o/preu treatment, and for Cyclofem group, immediately prior to the 3rd and gth injections and 1 and 3 weeks a/ter the 3rd and gth injections, for Ortho Novum group, blood samples were taken on the irst day o[.the 3rd and gth pill cycles and 1 and 3 weeks later in both cycles. For both groups after at least 3 months nonhormonal method of contraception, blood sampling was repeated at follicular and luteal phases of a normal mentrual cycle.Coagulation and librinolysis parameter were detected including hemoglobin,platelet count, prothrombin time, APTT, fibrinogen, factor Vll, [actor X,plasminogen, in PAl, AT Ill (functional and immunological assays) and protein C.In the Cyclolem group, hemoglobin, platelet count, fibrinogen and /Octor X were not changed. Factor Vll significantly reduced. Prothrombin time and APTT showed minor changes. Plasminogen and protein C decreased while t-- PAl and AT 11.1 increased. These changes showed a dynamic balance between coagulatioll and fibrinolysis. In Ortho---Novum 1/35 group, platelet count, jactor X and [ibrinogen increased and prothrombin time and APTT accelerated. In fibrinolysis and anticoagulation system, plasminogen increased as well as protein C, but AT Ill declined. Those changes showed a tendency o[ hyper-coagulabllity state, fibrinolysis and anticoagulation were enhanced to a certain extent.The result of our study is that there are slight 'changes on coagulation and [ibrinolyls is in Cyclofem injectable contraceptive users.
文摘The effects of consecutively using the contraceptive injections (Mesigyna or Cyclofem) on both blood coagulation and fibrinolysis were evaluated on 94 Chinese women who had been injected with one of these two injections once a month for 9 months. To provide the evidences on the safety of long term use, relevant parameters were observed before the treatment, after the injection 3 and 9, as well as 3 months after drug withdrawing. The results were as follows: Among those who had been injected with Mesigyna, the levels of factor VII and factor X declined significantly during treatment. The activity of AT Ⅲ, plasminogen and the concentration of protein C also decreased. Moreover, the corresponding parameters did not recovered to the normal level after stopping treatment. Prothrombin time (PT) and activated partial thromboplastin time (APTT) were prolonged in the early period of treatment, but recovered to the normal at week 47 (injection withdrawn). No or slight change was observed in other parameters. Among the woman injected with Cyclofem, the concentrations of factor VII and plasminogen decreased over time, while the tissue plasminogen activator inhibitor (t PAI) levels increased after the 9 th injection and recovered to normal at week 47 after discontinuation of treatment. The results suggested that some significant parameter changes of coagulation and of fibrinolysis could be detected among long term users, but their impact on the fibrinolysis system was not obvious. The observed phenomenon did not show a tendency to facilitate thromboembolism and possibility of being harmful to the users. Thus, the observed changes should be regarded as the reactions to keep the equilibrium between coagulation and fibrinolysis and had no marked clinical pathological significance on the users.
